GSK's Consumer Segment Grows 7% With Heavy Investment In R&D And A&P
This article was originally published in The Tan Sheet
Executive Summary
Increased investment in brand innovation and high-quality, high-volume advertising are the "underpinning" of GlaxoSmithKline's consumer segment's "spectacular year," according to CEO Andrew Witty
You may also be interested in...
GSK Expands In Korea With Purchase Of Equity Stake In Dong-A Pharma
GlaxoSmithKline is paying 142.9 billion South Korean won ($128.7 million) to acquire a 9.9 percent stake in Dong-A Pharmaceutical, South Korea's leading Rx and OTC company. The strategic alliance should help GSK gain share in the rapidly growing Korean pharmaceutical market
GSK Expands In Korea With Purchase Of Equity Stake In Dong-A Pharma
GlaxoSmithKline is paying 142.9 billion South Korean won ($128.7 million) to acquire a 9.9 percent stake in Dong-A Pharmaceutical, South Korea's leading Rx and OTC company. The strategic alliance should help GSK gain share in the rapidly growing Korean pharmaceutical market
GSK Expands In Korea With Purchase Of Equity Stake In Dong-A Pharma
GlaxoSmithKline is paying 142.9 billion South Korean won ($128.7 million) to acquire a 9.9 percent stake in Dong-A Pharmaceutical, South Korea's leading Rx and OTC company. The strategic alliance should help GSK gain share in the rapidly growing Korean pharmaceutical market